Could a pill slow down metastatic breast cancer?
NCT ID NCT04280536
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an oral chemotherapy drug called Lonsurf in people with metastatic breast cancer that has spread. The trial includes two groups: those who have had a certain type of chemo before and those who haven't. Researchers want to see if Lonsurf can stop the cancer from growing for at least 4 to 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lonsurf (trifluridine/tipiracil, also known as TAS-102)
- What this could lead to
- If successful, this could provide a new oral chemotherapy option for people with metastatic breast cancer who have run out of standard treatments.
- What could go wrong
- This is an early-phase trial with only 86 participants, so results may not apply to all patients. The drug may cause side effects like low blood cell counts or fatigue, and it may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Hospital
Singapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?